Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0140 in Primary Aldosteronism
NCT07646535Phase 2Not yet recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0140 in primary aldosteronism (PA), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SAL0140
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT07646535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646535.